Immix Biopharma Net Income Over Time
| IMMX Stock | USD 7.43 0.59 8.63% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immix Biopharma Performance and Immix Biopharma Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immix Biopharma. Market participants price Immix higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immix Biopharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Immix Biopharma's market price often diverges from its book value, the accounting figure shown on Immix's balance sheet. Smart investors calculate Immix Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Immix Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immix Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immix Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immix Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Immix Biopharma and related stocks such as Coya Therapeutics Common, Whitehawk Therapeutics, and Oncolytics Biotech Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COYA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.9 M) | (12.2 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| WHWK | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (3.5 M) | (110.1 M) | (60.5 M) | (65.8 M) | (63.7 M) | (57.3 M) | (60.2 M) |
| ONCY | (574.5 K) | (29 M) | (36.4 M) | (23.5 M) | (18.6 M) | (13.7 M) | (15.1 M) | (15.6 M) | (17 M) | (45.6 M) | (16.8 M) | (21 M) | (19.1 M) | (20.6 M) | (31.7 M) | (28.5 M) | (27.1 M) |
| ZNTL | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (45.7 M) | (117.8 M) | (158.7 M) | (236.8 M) | (292.2 M) | (165.8 M) | (149.3 M) | (156.7 M) |
| SRZN | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (32.6 M) | (52.5 M) | (27.7 M) | (43 M) | (63.6 M) | (57.2 M) | (60.1 M) |
| ATOS | (122.9 K) | (3.4 M) | (5.1 M) | (10.8 M) | (14.7 M) | (15.8 M) | (6.4 M) | (8.1 M) | (11.4 M) | (17.2 M) | (17.8 M) | (20.6 M) | (26.2 M) | (30.1 M) | (25.5 M) | (23 M) | (21.8 M) |
| TIL | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (37.7 M) | (156.8 M) | (223.2 M) | (156.1 M) | (74.1 M) | (66.7 M) | (70.1 M) |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| ORMP | (50 K) | (1.6 M) | (3.3 M) | (4.2 M) | (5.7 M) | (7.2 M) | (11 M) | (10.5 M) | (12.7 M) | (14.4 M) | (11.5 M) | (22.2 M) | (37.8 M) | 5.5 M | (19.1 M) | (17.2 M) | (16.3 M) |
Immix Biopharma and related stocks such as Coya Therapeutics Common, Whitehawk Therapeutics, and Oncolytics Biotech Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Immix Biopharma financial statement analysis. It represents the amount of money remaining after all of Immix Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Immix Biopharma | IMMX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 11400 West Olympic |
| Exchange | NASDAQ Exchange |
USD 7.43
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.